v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Cash flows from operating activities:    
Net loss $ (12,683,708) $ (5,552,875)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 4,054,351 2,367,042
Research and development expense - license acquired 0 1,046,965
Change in fair value of warrant liabilities 909,474 51,942
Depreciation and amortization 230,715 8,820
Loss on disposal of fixed asset 3,230 0
Equity in losses on equity method investment 218,589 0
Non-cash amortization on convertible notes 0 88,587
Non-cash interest expense on convertible notes 0 30,155
Changes in operating assets and liabilities    
Prepaid insurance, other prepaid expenses and current assets 117,068 (254,046)
Long-term prepaid insurance 145,250 0
Accounts payable (166,684) 1,611,444
Accrued expenses and other current liabilities 29,375 207,187
Net cash used in operating activities (7,142,340) (394,779)
Cash flows from investing activities    
Purchase of laboratory and office equipment (362,915) (281,917)
Payment of transaction costs for licenses acquired 0 (43,463)
Cash paid for license acquired 0 (54,000)
Net cash used in investing activities (362,915) (379,380)
Cash flows from financing activities    
Principal payment of financed insurance (167,925) (8,814)
Proceeds from issuance of stock, net of issuance costs 33,283,970 0
Proceeds from issuance of convertible notes 0 600,000
Proceeds from issuance of common shares for services 0 1,474
Proceeds from prefunded warrant 0 10
Repurchase of common stock 0 (14)
Net cash provided by financing activities 33,116,045 592,656
Net increase (decrease) in cash and cash equivalents 25,610,790 (181,503)
Cash and cash equivalents, beginning of period 10,313,966 249,600
Cash and cash equivalents, end of period 35,924,756 68,097
Supplemental disclosure of cash flow information:    
Cash paid for interest 3,244 0
Cash paid for income taxes 0 0
Non-cash investing and financing activities:    
Issuance of common stock for research and development expense- licenses acquired 0 844,600
Fair value of warrant liability issued for research and development expense- licenses acquired 0 104,902
Insurance financed through note payable $ 365,430 $ 90,000

Source